Choi YS, et al. - Authors sought to inspect the clinical course of ulcerative proctitis (UP) with skip inflammation in the right side of the colon and the efficacy of topical 5-aminosalicylate (5-ASA) monotherapy in patients with an initial diagnosis of UP from January 2005 to October 2015. Both UP with skip inflammation and typical UP did not exhibit different clinical course. It was determined that the overall acute exacerbation rates for the control and skip inflammation groups were 17.2% and 26.8% at 10 years, respectively. Yielded results illustrated that topical 5-ASA monotherapy for maintaining remission was as effective as 5-ASA combination therapy, regardless of the presence of skip lesions.